Gilead Sciences, Inc.
anito-cel
multiple myeloma
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on anito-cel for multiple myeloma is expected Date TBD.
Primary source
· SEC 8-K
verified 14h ago
“Upon FDA approval of anito-cel, the proposed transaction is expected to be accretive to earnings per share in 2028 and thereafter.”